Table 1 Baseline characteristics of the patients included in the DECA criteria for AC severity and control validation study (N = 128)
From: Validation of the DECA criteria for allergic conjunctivitis severity and control
Age, years, mean (SD) | 34.4 (12.1) |
Gender, female, N (%) | 93 (72.7) |
Allergic comorbidities, N (%) | |
AR | 128 (100.0) |
Asthma | 53 (41.4) |
Atopic dermatitis | 14 (10.9) |
Urticaria | 11 (8.6) |
Contact dermatitis | 4 (3.1) |
Food allergy | 4 (3.1) |
Other | 14 (10.9) |
Type of AC sensitization, N (%) | |
Perennial | 40 (32.5) |
Seasonal | 31 (25.2) |
Both | 52 (42.3) |
rTOSS score, mean (SD) | 5.4 (2.3) |
Hyperemia (Efron scale), N (%) | |
Normal | 26 (20.3) |
Trace | 62 (48.4) |
Mild | 29 (22.7) |
Moderate | 11 (8.6) |
AC duration, N (%) | |
Intermittent | 44 (34.4) |
Persistent | 84 (65.6) |
Items reported (DECA), N (%) | |
Bothersome symptoms | 116 (90.6) |
Affecting vision | 39 (30.5) |
Interference with academic or work tasks | 54 (42.2) |
Interference with daily activity, reading, sport | 66 (51.6) |
Severity (DECA criteria), N (%) | |
Mild (no items affected) | 10 (7.8) |
Moderate (1–3 items affected) | 93 (72.7) |
Severe (4 items affected) | 25 (19.5) |
Control (DECA criteria), N (%) | |
Controlled | 27 (21.1) |
Not controlled | 101 (78.9) |
Ophthalmic treatments at baseline, N (%) | |
Azelastine | 34 (26.6) |
Ketotifen | 11 (8.6) |
Olopatadine | 3 (2.3) |
Levocabastine | 1 (0.8) |
Others | 1 (0.8) |
Nasal treatments at baseline, N (%) | |
Budesonide | 2 (1.6) |
Fluticasone | 12 (9.4) |
Mometasone | 22 (17.2) |
Triamcinolone | 1 (0.8) |
Fluticasone furoate | 43 (33.6) |
Fluticasone/azelastine combination | 41 (32.0) |